Compare ADMA Biologics Inc (ADMA) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Canadian Natural Resources Ltd. — how do they compare? ADMA Biologics Inc trades at $9.85 (market cap $2.22B), while Canadian Natural Resources Ltd. trades at $47.83 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 44.2× ADMA Biologics Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CNQ | |
|---|---|---|
Market Cap | $2.22B | $98.11B |
Sector | Health | Energy |
52-Week High | $20.38 | $50.55 |
52-Week Low | $7.60 | $29.31 |
Enterprise Value | $2.29B | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Canadian Natural Resources (CNQ) trades at $47.845, up 1.26% today, with a bullish technical signal and strong earnings momentum after Q2 2026 EPS beat estimates. The company shows robust profitability with a 22.87% net margin and 26.69% ROE, supported by record production and disciplined capital spending. Recent news highlights dividend reliability and operational strength, with analyst consensus heavily favoring buy ratings.
CNQ presents a compelling investment case with attractive valuation (P/E 11.82), consistent dividend payouts, and positive cash flow trends. Key risks include oil price volatility and rising debt levels, but the company's scale and efficiency underpin resilience. Wall Street optimism, with 27 buy ratings, suggests further upside potential amid stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
